Modulation of cell surface protein expression by infection with HIV-1

Leukemia

Volumn 13, Issue , 1999, Pages 99-105

  Speth, C ^a   Dierich, M P ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Adhesion; Apoptosis; Complement; Costimulation; HIV; Protein expression

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CELL ADHESION MOLECULE; COMPLEMENT RECEPTOR; CYTOKINE RECEPTOR; INTERLEUKIN 2 RECEPTOR; MEMBRANE PROTEIN;

APOPTOSIS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; REVIEW;

ANTIGENS, CD28; ANTIGENS, CD80; APOPTOSIS; CELL ADHESION MOLECULES; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE PROTEINS; RECEPTORS, COMPLEMENT; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-2;

EID: 0033111018     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2401322     Document Type: Article

References (85)

1. Chen YH, Böck G, Vornhagen R, Steindl F, Katinger H, Dierich MP. HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41. Mol Immunol 1994; 31: 977-982.
2. Wrightham M, Schimpf A, Pennington TH, Walker F, Sewell HF. HIV induces modulation of functionally important cellular antigens. Clin Exp Immunol 1991; 85: 75-79.
3. Bandres JC, Shaw AS, Ratner L. HIV-1 Nef protein downregulation of CD4 surface expression: relevance of the lck binding domain of CD4. Virology 1995; 207: 338-341.
4. Cucchiarini M, Cagnon L, Giordanengo V, Doglio A, Lefebvre JC. Induction by human immunodeficiency viruses types 1 and 2 of degradation of CD4 but not of a CD4 mutant unable to bind viral envelope glycoproteins. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 427-436.
5. Fujita K, Masldarelli F, Silver J. Bimodal down-regulation of CD4 in cells expressing human immunodeficiency virus type 1 Vpu and Env. J Gen Virol 1996; 77: 2393-2401.
6. Koka P, Yunis J, Passarelli AL, Dubey DP, Faller DV, Ynis EJ. Increased expression of CD4 molecules on Jurkat cells mediated by human immunodeficiency virus tat protein. J Virol 1988; 62: 4353-4357.
7. Rhee SS, Marsh JW. Human immunodefiency virus type 1 Nefinduced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol 1994; 68: 5156-5163.
8. Scheppler JA, Nicholson JK, Swan DC, Ahmed-Ansari A, McDougal JS. Down-modulation of MHC-1 in a CD4T cell line, CEME5, after HIV-1 infection. J Immunol 1989; 143: 2858-2866.
9. Kerkau T, Gernert S, Kneitz C, Schimpl A. Mechanism of MHC class I downregulation in HIV infected cells. Immunobiology 1992; 184: 402-409.
10. Kerkau T, Bacik I, Bennink JR, Yewdell JW, Hunig T, Schimpl A, Schubert U. The human immunodeficiency virus type I (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997; 185: 1295-1305.
11. Schwartz O, Marechal V, Le-Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nature Med 1996; 2: 338-342.
12. Chen YH, Bock G, Vornhagen R, Steindl F, Katinger H, Dierich MP. HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells. Int Arch Allergy Immunol 1994; 104: 227-231.
13. Orlikowsky T, Wang ZQ, Dudhane A, Horowitz H, Conti B, Hoffmann M. The cell surface marker phenotype of macrophages from HIV-1-infected subjects reflects an IL-10-enriched and IFNg-deprived donor environment. J Inter Cytok Res 1996; 16: 957-962.
14. Willard-Gallo KE, Delmelle-Wibaut C, Segura-Zapata I, Janssens M, Willems L, Kettmann R. Modulation of CD3-g gene expression after HIV-1 infection of the WEI7/10 T cell line is progressive and occurs in concert with decreased production of viral p24 antigen. AIDS Res Hum Retroviruses 1996; 12: 715-725.
15. Roos MT, Miedema F, Meinesz AP, De Leeuw NA, Pakker NG, Lange JM, Coutinho RA, Schellekens PT. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin Exp Immunol 1996; 105: 409-415.
16. + T cells. J Immunol 1997; 158: 1551-1558.
17. Pascual M, Danielsson C, Steiger G, Schifferli JA. Proteolytic cleavage of CRI on human erythrocytes in vivo: evidence for enhanced cleavage in AIDS. Eur J Immunol 1994; 24: 702-708.
18. Munson LG, Scott ME, Landay AL, Spear GT. Decreased levels of complement receptor I (CD35) on B lymphocytes in persons with HIV infection. Clin Immunol Immunopathol 1995; 75: 20-25.
19. Larcher C, Schulz TF, Hofbauer J, Hengster P, Romani N, Wachter H, Dierich MP. Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells. J Acquir Immune Defic Syndr 1990; 3: 103-108.
20. Larcher C, Julen N, Prodinger WM, Totsch M, Gurtler L, Dierich MP. Reduced CD21 (CR2) and CD54 (ICAM-1) expression in MT2 cells with HIV-1 or HIV-2 strains. Immunol Lett 1995; 46: 31-36.
21. Speth C, Mair M, Pichler I, Stöckl G, Dierich MP. Regulation of cell surface protein expression by HIV-1. Virus Res 1997; 47: 118.
22. Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, Chenoweth DE, Arthur LO, Farrar WL, Wahl LM. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 1989; 142: 3553-3559.
23. Jarvis JN, Taylor H, Long PM, Gutta PV, Pousak T, Fine N. Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 249-256.
24. Maroder M, Scarpa S, Screpanti I, Stigliano A, Meco D, Vacca A, Stuppia L, Frati L, Modesti A, Gulino A. Human immunodefiency virus type 1 tat protein modulates fibronectin expression in thymic epithelial cells and impairs in vitro thymocyte development. Cell Immunol 1996; 168: 49-58.
25. Wang L, Robb CW, Cloyd MW. HIV induces homing of resting T lymphocytes to lymph nodes. Virology 1997; 228: 141-152.
26. Oyaizu N, McCloskey TW, Than S, Hu R, Pahwa S. Mechanism of apoptosis in peripheral blood mononuclear cells of HIV-infected pations. Adv Exp Med Biol 1995; 374: 101-114.
27. + T lymphocytes during HIV infection. J Immunol 1996; 156: 2282-2293.
28. Huang L, Li CJ, Pardee AB. Human immunodeficiency virus type 1 Tat protein activates B lymphocytes. Biochem Biophys Res Commun 1997; 237: 461-464.
29. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996; 70: 199-206.
30. + T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology 1996; 87: 581-585.
31. Bohler T, Herr I, Debatin KM, Geiss M, Haas J. Downregulation of increased CD95(Apo-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy. Blood 1997; 90: 886-888.
32. + T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 1995; 11: 31-40.
33. Bani L, David D, Fevrier M, Pialoux G, Dupont B, Sugamura K, Theze J. Interleukin-2 receptor beta and gamma chain dysregulation during the inhibition of CD4 T cell activation by human immunodeficiency virus-1 gp 120. Eur J Immunol 1997; 27: 2188-2194.
34. Greenway AL, McPhee DA, Grgacic E, Hewish D, Lucantoni A, Macreadie I, Azad A. Nef 27. but not the Nef 25 isoform of human immunodeficiency virus-type 1 pNL4.3 down-regulates surface CD4 and IL-2R expression in peripheral blood mononuclear cells and transformed T cells. Virology 1994; 198: 245-256.
35. Pocsik E, Higuchi M, Aggarwal BB. Down-modulation of cell surface expression of p80 form of the tumor necrosis factzor receptor by human immunodeficiency virus-1 tat gene. Lymphokine Cytokine Res 1992; 11: 317-325.
36. Puri RK, Aggarwal BB. Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. Cancer Res 1992; 52: 3787-3790.
37. + T cells down-regulates the expression of CD28: effect on T cell activation and cytokine production. Clin Immunol Immunopathol 1995; 77: 262-270.
38. Goeman J, Gigase PL, De Boer M, Ceuppens JL. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8 T cells from HIVinfected subjects. Clin Exp Immunol 1995; 100: 425-433.
39. Dudhane A, Conti B, Orlikowskyy T, Wang ZQ, Mangla N, Gupta A, Wormser GP, Hoffmann MK. Monocytes in HIV type 1-infected individuals lose expression of costimulatory B7 molecules and acquire cytotoxic activity. AIDS Res Hum Retroviruses 1996; 12: 885-892.
40. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15: 641-646.
41. Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, Kawamoto S, Sasaki S et al. Immunomodulatory effects of a plasmid expressing B7-2 on human immunideficiency virus-1-specific cellmediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 1997; 27: 782-787.
42. Schifferli JA, Ng YC, Paccaud JP, Walport MJ. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol 1989; 75: 329-335.
43. Ahearn JM, Fearon DT. Structure and function of the complement receptors. CRI (CD35) and CR2 (CD21). Adv Immunol 1989; 46: 183-219.
44. Tausk F, Gigli I. The human C3b receptor: function and role in human diseases. J Invest Dermatol 1990; 94 (Suppl. 6): 141S-145S.
45. Tausk FA, McCutchan A, Spechko P, Schreiber RD, Gigli I. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest 1986; 78: 977-982.
46. Jouvin MH, Rozenbaum W, Russo R, Kazatchkine MD. Decreased expression of the C3b/C4b complement receptor (CRI) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1987; 1: 89-94.
47. Carter RH, Fearon DT. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-lgM. J Immunol 1989; 143: 1755-1760.
48. Mitomo K, Fujita T, Iida K. Functional and antigenic properties of complement receptor type 2, CR2. J Exp Med 1987; 165: 1424-1429.
49. + cells in HIV-infected persons. Immunology 1992; 75: 59-65.
50. Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D. Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 1990; 162: 1227-1232.
51. Sanchez-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1) the C3bi complement receptor (OKMI/Mac-1), and the p150, 95 molecule. J Exp Med 1983; 158: 1785-1803.
52. Diamond MS, Garcia Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol 1993; 120: 1031-1043.
53. Ueda T, Rieu P, Brayer J, Arnaout MA. Identification of the complement iC3b binding site in the beta 2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci USA 1994; 91: 10680-10684.
54. Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994; 12: 775-808.
55. von Andrian UH, Chambers JD, McEvoy LM, Bargatze RF, Arfors KE, Butcher EC. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proc Natl Acad Sci USA 1991; 88: 7538-7542.
56. Tedder TF, Penta AC, Levine HB, Freedman AS. Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol 1990; 144: 532-540.
57. Davignon D, Martz E, Reynolds T, Kurzinger K, Springer TA. Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2, 3 that participates in T lymphocyte-mediated killing. Proc Natl Acad Sci USA 1981; 78: 4535-4539.
58. Yong K, Khwaja A. Leucocyte cellular adhesion molecules. Blood Rev 1990; 4: 211-225.
59. Ng TT, Guntermann C, Nye KE, Parkin JM, Anderson J, Norman JE, Morrow WJ. Adhesion co-receptor expression and intracellular signalling in HIV disease: implications for immunotherapy. AIDS Res Hum Retroviruses 1995; 11: 547-553.
60. Dhawan S, Weeks BS, Soderland C, Schnaper HW, Toro LA et al. HIV-1 infection alters monocyte interactions with human microvascular endothelial cells. J Immunol 1995; 154: 422-432.
61. Fortin JF, Cantin R, Lamontagne G, Tremblay M. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997; 71: 3588-3596.
62. Shattock RJ, Griffin GE. Cellular adherence enhances HIV replication in monocytic cells. Res Virol 1994; 145: 139-145.
63. + T-cell clone. Comparative analysis of Fas-mediated cytotoxicity between a Thybridoma and a T-cell clone. Immunol Lett 1997; 55: 53-60.
64. Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P. Differential ability of T cell subsets to undergo activationinduced cell death. Proc Natl Acad Sci USA 1997; 94: 5778-5783.
65. Lowin B, Hahne M, Mattman C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652.
66. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
67. + T cells from HIV-infected patients increases with disease progression. J Mol Med 1995; 73: 591-593.
68. Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, Erb P. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS 1996; 10: 9-16.
69. Silvestris F, Cafforio P, Frassanito MA, Tucci M, Romito A, Nagata S, Dammacco F. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. AIDS 1996; 10: 131-141.
70. McCloskey TW, Oyaizu N, Kaplan M, Pahwa S. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry 1995; 22: 111-114.
71. + lymphocyte depletion and human immunodeficiency virus replication. Blood 1997; 89: 1357-1363.
72. Glynn JM, McElligott DL, Mosier DE. Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas (CD95) antagonist. J Immunol 1996; 157: 2754-2758.
73. + T lymphocytes is not mediated by Fas-Fas ligand. AIDS 1997; 11: 1671-1680.
74. + T cells. Proc Natl Acad Sci USA 1996; 93: 11014-11018.
75. Hashimoto F, Oyaizu N, Kalyanaraman VS, Pahwa S. Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2. Blood 1997; 90: 745-753.
76. + T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J Immunol 1997; 158: 2456-2463.
77. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103: 161-179.
78. + T cell loss in HIV-1 infection. Springer Semin Immunopathol 1997; 18: 285-303.
79. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993; 167: 519-525.
80. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleuin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177: 483-492.
81. Teppler H, Kaplan G, Smith K, Cameron P, Montana A, Meyn P, Cohn Z. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-298.
82. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane HC. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. New Engl J Med 1995; 332: 567-575.
83. Bani L, David D, Fevrier M, Pialoux G, Dupont B, Sugamura K, Theze J. Interleukin-2 receptor beta and gamma chain dysregulation during the inhibition of CD4 T cell activation by human immunodeficiency virus-1 gp120. Eur J Immunol 1997; 27: 2188-2194.
84. Chopra RK, Raj NB, Scally JP, Donnenberg AD, Adler WH, Saah AJ, Margolick JB. Relationship between IL-2 receptor expression and proliferative responses in lymphocytes from HIV-1 seropositive homosexual men. Clin Exp Immunol 1993; 91: 18-24.
85. Barcova M, Kacani L, Speth C, Dierich MP. gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-g production. J Infect Dis 1998; 177: 905-913.